USD 0.9 billion
Doxorubicin Market Size, Share, Growth Analysis, By Formulation(Lyophilized Powder, Doxorubicin Injection), By Application(Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma), By Distribution(Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35A2310 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|Tables:
34
|Figures:
74
Doxorubicin Market Insights
Doxorubicin Market size was valued at USD 1056.33 Million in 2023 and is poised to grow from USD 1127.1 Million in 2024 to USD 1893.56 Million by 2032, growing at a CAGR of 6.70% during the forecast period (2025-2032).
Doxorubicin, a potent chemotherapeutic agent belonging to the anthracycline class, has dominated the global market. Its widespread use and demand are attributed to its effectiveness in the treatment of cancers including breast, lung and leukemia.
According to the World Cancer Research Fund International, nearly 20 million people worldwide were diagnosed with cancer in 2022. As the aging population expands, the need for effective cancer treatments including doxorubicin is expected to increase. Advances in drug delivery and drug development enhance the efficacy and safety of doxorubicin, leading to greater acceptance and use in a variety of cancer therapies.
Governments of different countries are taking several initiatives to spread awareness and introduce new therapy methods for cancer, which may boost the market's growth over the forecast period. For instance, the National Comprehensive Cancer Control Program, in 2020, provided funding, guidance, and technical assistance to help the programs implement plans to prevent and control cancer, which may provide opportunities for key players to launch new products into the market and boost the market's growth. Thus, the abovementioned factors are expected to boost the market significantly. However, side effects associated with doxorubicin are expected to restrain the market's growth.
Furthermore, research and development activities targeted by pharmaceutical companies to develop new drugs and combination therapies related to doxorubicin is a major factor driving the growth of the market. High levels of investment and focus highly personalized drugs will provide new opportunities for doxorubicin market expansion.
US Doxorubicin Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Hospitals Pharmacies
Fastest Growth
Leukemia
Growth Rate
5.8% CAGR
Global Doxorubicin Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Doxorubicin Market Segmental Analysis
Global Doxorubicin Market is segmented by Formulation, Application, application, end user and region. Based on Formulation, the market is segmented into Lyophilized Powder, and Doxorubicin Injection. Based on Application, the market is segmented into Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Other. Based on Distribution, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Drug Formulation
Innovations in drug delivery systems including the development of liposomal doxorubicin have enabled injectable doxorubicin injections and improved protection. Liposomal formulations encapsulate doxorubicin in lipid spheres, which enhances drug delivery to cancer cells and reduces the systemic toxicity. In addition, extended-launch medicinal drugs are designed to increase the period of action and decrease aspect results. These advances are enhancing and increasing patient outcomes doxorubicin injection into therapeutic packages. This is the authentic formula of the drug and has been widely used in most cancers' treatment for many years. It is usually administered intravenously and works via interfering with the DNA synthesis of most cancers' cells, preventing their replication and boom.
Lyophilized powder is expected to register the fastest CAGR of 7.1% during the forecast period. Lyophilization or freeze-drying converts doxorubicin into a stable, biodegradable dry powder. This consistency is important to maintain the potency and effectiveness of the product for the duration of its lifestyles cycle. Demand for lyophilized powdered doxorubicin is increasing because of its verified efficacy within the remedy of cancers including breast, prostate, ovarian, lung, bladder, gastric cancer and leukemia. Liposomal Doxorubicin has proven promise in treating the positive types of most cancers, such as ovarian cancers, myeloma, and its use is predicted to grow within the coming years.
Analysis by Application
The breast cancer segment is dominating and accounts for the highest market revenue in 2023. Breast cancer plays a widespread position in using the demand for doxorubicin within the market. As one of the most prevalent cancers globally, breast cancer accounts for an enormous part of the doxorubicin's clinical applications. Breast cancer is the most commonplace most cancers in women, and its incidence continues to rise due to elements such as the growing older populace, genetics due to adjustments in behavior and lifestyle. These increasing rates, which are also a major cause of cancer-related deaths, are driving the search for effective therapies, including doxorubicin, which is a keystone in breast cancer chemotherapy.
The bladder cancer segment is expected to grow at a significant CAGR during the forecast period. Bladder cancer, though less common than breast cancer, also contributes significantly to the doxorubicin market. Doxorubicin is used as part of the chemotherapy regimen for muscle-invasive bladder cancer and as neoadjuvant therapy to shrink tumors before surgery. Bladder cancer is one of the most common cancers of the nervous system, with global diagnosis rates rising due to factors such as an aging population, smoking and occupational exposure to carcinogens because of their involvement. According to the American Cancer Society Establishment as a treatment for advanced tumors, doxorubicin is a key component in the management of the disease.
Global Doxorubicin Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Doxorubicin Market Regional Insights
As per doxorubicin market outlook, North America is dominating. North America had the largest market share of doxorubicin market with 37.7% in 2023. North America, especially the US. and Canada have some of the highest rates of cancer in 2024. According to the American Cancer Society, there are expected to be 1.9 million new cases of cancer in the US. that year. The doxorubicin market dominated the regional market. Research programs with several leading cancer research institutes and pharmaceutical companies focused on improving existing cancer treatments and discovering new therapies.
Asia Pacific in the doxorubicin market is expected to register the fastest CAGR during the forecast period. The growing investments in healthcare infrastructure, expansion of pharmaceutical industries, and government initiatives to improve cancer treatment and care further propel the growth of the market in the Asia Pacific region. India has witnessed a sharp rise in cancer in recent years due to factors such as aging population, lifestyle changes and environmental factors. Additionally, the rising incidence of the cancer, particularly in countries like China and India, contributes to the demand for the Doxorubicin.
Global Doxorubicin Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Doxorubicin Market Dynamics
Doxorubicin Market Drivers
Increasing Incidence of Cancer
- The increasing incidence of cancer across the globe is a major driver for the doxorubicin industry. Doxorubicin, a potent anticancer drug, is widely used to treat a variety of cancers, including breast cancer, ovarian cancer, leukemia, and lymphoma. According to global cancer statistics, the increasing burden of these diseases, especially in developing countries, has greatly increased the demand for effective cancer treatment.
Advancements in Drug Delivery Systems
- Another important component is the development of recent formulations for doxorubicin-related drug delivery, which includes liposomal formulations and nanoparticle-based providers. For example, liposomal doxorubicin enhances drug delivery to cancer cells and decreases the systemic toxicity, thereby enhancing patient results. These advanced formulations have received sizable traction because of reduced aspect effects and better healing efficacy.
Doxorubicin Market Restraints
Severe Side Effects and Toxicity Concerns
- One of the major challenges hampering doxorubicin market growth is the associated toxicities. Doxorubicin is known to be cardiotoxic and can cause chronic cardiac complications in patients undergoing treatment. This raised concerns among health professionals and patients, leading to the approval of alternative treatments with fewer side effects. Furthermore, the drug's ability to cause nausea, inflammation and myelosuppression limits its tolerance in certain patient groups, thus hampering its market.
High Cost of Advanced Pharmaceuticals
- Newer formulations such as liposomal doxorubicin provide improved safety profiles; their high cost is a major obstacle. The affordability of advanced doxorubicin products is a pressing issue, as the majority of cancer patients in developing regions lack access to expensive therapies. This cost factor, coupled with limited insurance coverage in some regions, has restrained the adoption of these advanced drugs, impacting doxorubicin market growth.
Request Free Customization of this report to help us to meet your business objectives.
Doxorubicin Market Competitive Landscape
A notable example of competition in the doxorubicin market is the liposomal formulation Doxil, developed by Janssen Pharmaceuticals, a division of Johnson & Johnson Doxil has a competitive advantage over the conventional doxorubicin, due to its ability to deliver the drug tumors directly. The doxorubicin industry is competitive and diverse, with several large pharmaceutical companies. Competition from major market players with doxorubicin formulations provides a variety of medications, including traditional intravenous (IV) formulations, liposomal formulations and generic formulations.
Doxorubicin Market Top Player’s Company Profiles
- Johnson & Johnson Services, Inc. (US)
- Sun Pharmaceutical Industries Ltd (India)
- Cipla (India)
- Cadila Pharmaceuticals (India)
- Novartis AG (Switzerland)
- Dr. Reddy’s Laboratories Ltd. (India)
- SRS Life Sciences (Switzerland)
- MicroBiopharm Japan Co., Ltd. (Japan)
- Baxter (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Hikma Pharmaceuticals PLC (UK)
- Sanofi S.A. (France)
- Fresenius Kabi AG (Germany)
- Eli Lilly and Company (US)
- Apotex Inc. (Canada)
- Intas Pharmaceuticals Ltd. (India)
- Janssen Pharmaceuticals, Inc. (US)
- Accord Healthcare Ltd. (UK)
- Alkem Laboratories Ltd. (India)
- Wockhardt Ltd. (India)
- Zydus Cadila (India)
Doxorubicin Market Recent Developments
- In February 2024, Bristol-Myers Squibb announced the acquisition of Mirati Therapeutics, which incorporates the development of recent therapeutic alternatives related to doxorubicin. The acquisition is vast as it pursuits to grow BMS' oncology pipeline, which might also encompass new drug combos or upgrades to present pills which includes doxorubicin.
- In October 2021, Padagis, in partnership with Ayana Pharma Ltd, received approval from the US FDA to launch its AB-rated generic version of Doxil (Doxorubicin Liposome Injection).
- In March 2021, Genentech applied for Polyvi (polatuzumab vedotin) combined with Rituxan (rituximab) combined with cyclophosphamide, doxorubicin, and prednisone (R-CHP), Rituxan and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Doxorubicin Key Market Trends
- Rising Adoption of Liposomal Doxorubicin: Liposomal doxorubicin formulations such as the Doxil are gaining popularity due to their ability to reduce toxicity and effectively deliver drugs to tumor sites. The rising demand for liposomal formulations is supported by the ongoing R&D efforts and regulatory approvals expected to propel the market in the coming years. These improved formulations are particularly suitable for the elderly or high-risk patients who do not respond to conventional doxorubicin.
- Increasing Use in Combination Therapies: The major factor characterizing the doxorubicin market is its increasing inclusion in combination therapy. The combination of the doxorubicin with other chemotherapeutic agents, targeted therapies, or immunomodulatory agents has yielded promising results in terms of efficacy and improved survival. For example, doxorubicin is commonly used in combination with cyclophosphamide and paclitaxel for the treatment of breast cancer.
Doxorubicin Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, the doxorubicin market is driven by the rising incidence of cancer and advances in drug delivery, which have positioned it as a key player in oncology therapeutics. But with challenges such as severe side effects and pharmacokinetics the high cost of range limits its full potential. Trends such as the adoption of combination therapies and growing popularity of liposomal doxorubicin underscore the dynamic growth of the market. The rising burden of disease, many people are opting for this type of treatment, which may boost the market. Therefore, it is estimated that the breast cancer segment will show rapid growth over the forecast period.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 990 million |
| Market size value in 2031 | USD 1774.66 million |
| Growth Rate | 6.70% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Doxorubicin Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Doxorubicin Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Doxorubicin Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Doxorubicin Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Doxorubicin Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Doxorubicin Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
